TVTX
Price:
$18.25
Market Cap:
$1.59B
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in ...[Read more]
Industry
Biotechnology
IPO Date
2012-11-08
Stock Exchange
NASDAQ
Ticker
TVTX
According to Travere Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.95B. This represents a change of 76.65% compared to the average of 1.11B of the last 4 quarters.
The mean historical Enterprise Value of Travere Therapeutics, Inc. over the last ten years is 1.03B. The current 1.95B Enterprise Value has changed 18.79% with respect to the historical average. Over the past ten years (40 quarters), TVTX's Enterprise Value was at its highest in in the December 2021 quarter at 2.01B. The Enterprise Value was at its lowest in in the December 2014 quarter at 397.98M.
Average
1.03B
Median
888.42M
Minimum
372.09M
Maximum
1.95B
Discovering the peaks and valleys of Travere Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 298.65%
Maximum Annual Enterprise Value = 1.95B
Minimum Annual Increase = -39.86%
Minimum Annual Enterprise Value = 372.09M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.01B | -39.86% |
2022 | 1.69B | -13.66% |
2021 | 1.95B | 36.96% |
2020 | 1.43B | 91.79% |
2019 | 743.65M | -27.76% |
2018 | 1.03B | 35.00% |
2017 | 762.56M | 8.35% |
2016 | 703.79M | 7.70% |
2015 | 653.47M | 75.62% |
2014 | 372.09M | 298.65% |
The current Enterprise Value of Travere Therapeutics, Inc. (TVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.55B
5-year avg
1.36B
10-year avg
1.03B
Travere Therapeutics, Inc.’s Enterprise Value is greater than DICE Therapeutics, Inc. (1.82B), less than Cytokinetics, Incorporated (6.54B), greater than Ventyx Biosciences, Inc. (80.09M), greater than Cogent Biosciences, Inc. (929.30M), less than Nuvalent, Inc. (6.38B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Structure Therapeutics Inc. (1.75B), less than Revolution Medicines, Inc. (9.43B), less than Akero Therapeutics, Inc. (2.00B), less than Avidity Biosciences, Inc. (4.80B), less than Protagonist Therapeutics, Inc. (2.65B), greater than Stoke Therapeutics, Inc. (457.69M), greater than IDEAYA Biosciences, Inc. (1.93B), greater than AnaptysBio, Inc. (502.56M), greater than MeiraGTx Holdings plc (427.31M), greater than Keros Therapeutics, Inc. (1.75B), greater than Homology Medicines, Inc. (-103303255.00), less than Legend Biotech Corporation (7.40B), less than Vaxcyte, Inc. (10.01B), less than Apellis Pharmaceuticals, Inc. (3.90B),
Company | Enterprise Value | Market cap |
---|---|---|
1.82B | $2.27B | |
6.54B | $5.79B | |
80.09M | $130.81M | |
929.30M | $1.01B | |
6.38B | $6.75B | |
8.24B | $8.19B | |
1.75B | $1.91B | |
9.43B | $9.55B | |
2.00B | $2.28B | |
4.80B | $5.16B | |
2.65B | $2.77B | |
457.69M | $605.41M | |
1.93B | $2.32B | |
502.56M | $677.65M | |
427.31M | $463.45M | |
1.75B | $2.27B | |
-103303255.00 | $3.02M | |
7.40B | $7.51B | |
10.01B | $11.04B | |
3.90B | $3.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Travere Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Travere Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Travere Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Travere Therapeutics, Inc. (TVTX)?
What is the 3-year average Enterprise Value for Travere Therapeutics, Inc. (TVTX)?
What is the 5-year average Enterprise Value for Travere Therapeutics, Inc. (TVTX)?
How does the current Enterprise Value for Travere Therapeutics, Inc. (TVTX) compare to its historical average?